Welcome to our dedicated page for Nanobiotix S.A. SEC filings (Ticker: NBTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Spotting pivotal trial updates buried in a 300-page biotech filing is hard—especially when Nanobiotix’s NanoXray platform generates data across multiple tumor types. If you’re tracking cash runway, partnership milestones or dilution risk, each disclosure matters. Stock Titan gathers every Nanobiotix insider trading Form 4 transactions notice, 8-K clinical read-out, and detailed 10-K so you don’t miss a single development.
Here’s how the platform turns complexity into clarity:
- AI-powered summaries translate dense scientific language into plain English, making Nanobiotix SEC filings explained simply.
- Real-time alerts surface Nanobiotix Form 4 insider transactions real-time and highlight management’s confidence shifts.
- Interactive dashboards link trial cost lines in the Nanobiotix quarterly earnings report 10-Q filing to cash-burn metrics, offering instant Nanobiotix earnings report filing analysis.
Whether you need the Nanobiotix annual report 10-K simplified to gauge liquidity, an Nanobiotix 8-K material events explained alert for a new radiotherapy collaboration, or the latest Nanobiotix proxy statement executive compensation details, Stock Titan delivers comprehensive coverage the moment each form hits EDGAR. Investors use these insights to:
- Monitor R&D expense trends quarter over quarter
- Track Nanobiotix executive stock transactions Form 4 before key data releases
- Understand dilution potential from shelf registrations
- Compare trial timelines across oncology indications
Stop scrolling through PDFs. Start understanding Nanobiotix SEC documents with AI—and make informed decisions in minutes, not hours.
Nanobiotix S.A. reported interim results showing Total Revenue of €24.9 million for the six months ended June 30, 2025, driven primarily by a one‑off €21.2 million cumulative catch‑up from a contract modification with Janssen that increased the constrained transaction price. The company recorded a net loss of €5.4 million for the period and held €28.8 million of cash and equivalents as of June 30, 2025. Management estimates current resources finance operations into mid‑2026 and states additional liquidity of €8–10 million will be required over the next 12 months, creating a material uncertainty about going concern. The March 17, 2025 amendment shifts almost full financial responsibility for the NANORAY‑312 Phase 3 trial to Janssen and revises certain milestone amounts, adjusting total deal value to about $2.6 billion with royalties in the low‑teens to low‑20s percentages.
FAQ
What is the current stock price of Nanobiotix S.A. (NBTX)?
What is the market cap of Nanobiotix S.A. (NBTX)?
